Date: 2015-02-19
Type of information: Private placement
Company: VolitionRx (Singapore)
Investors:
Amount:
Funding type: private placement
Planned used: VolitionRx intends to use the proceeds of this offering to fund prospective colorectal trials with Hvidovre Hospital in Denmark and an ongoing study at University Hospital in Bonn, Germany, as well as for general working capital and other corporate purposes.
Others: * On February 12, 2015, VolitionRx, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, announced the closing of its public offering of 2,475,000 shares of its common stock, at an offering price of $3.75 per share. National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (OTCBB:NHLD) and Lake Street Capital Markets acted as joint book running managers for the offering. The Benchmark Company acted as co-manager for the offering.
Therapeutic area: Cancer - Oncology - Infectious diseases - Diagnostic
